Literature DB >> 2384545

Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

J Logan1, J S Fowler, N D Volkow, A P Wolf, S L Dewey, D J Schlyer, R R MacGregor, R Hitzemann, B Bendriem, S J Gatley.   

Abstract

A graphical method of analysis applicable to ligands that bind reversibly to receptors or enzymes requiring the simultaneous measurement of plasma and tissue radioactivities for multiple times after the injection of a radiolabeled tracer is presented. It is shown that there is a time t after which a plot of integral of t0ROI(t')dt'/ROI(t) versus integral of t0Cp(t')dt'/ROI(t) (where ROI and Cp are functions of time describing the variation of tissue radioactivity and plasma radioactivity, respectively) is linear with a slope that corresponds to the steady-state space of the ligand plus the plasma volume,.Vp. For a two-compartment model, the slope is given by lambda + Vp, where lambda is the partition coefficient and the intercept is -1/[kappa 2(1 + Vp/lambda)]. For a three-compartment model, the slope is lambda(1 + Bmax/Kd) + Vp and the intercept is -[1 + Bmax/Kd)/k2 + [koff(1 + Kd/Bmax)]-1) [1 + Vp/lambda(1 + Bmax/Kd)]-1 (where Bmax represents the concentration of ligand binding sites and Kd the equilibrium dissociation constant of the ligand-binding site complex, koff (k4) the ligand-binding site dissociation constant, and k2 is the transfer constant from tissue to plasma). This graphical method provides the ratio Bmax/Kd from the slope for comparison with in vitro measures of the same parameter. It also provides an easy, rapid method for comparison of the reproducibility of repeated measures in a single subject, for longitudinal or drug intervention protocols, or for comparing experimental results between subjects. Although the linearity of this plot holds when ROI/Cp is constant, it can be shown that, for many systems, linearity is effectively reached some time before this. This analysis has been applied to data from [N-methyl-11C]-(-)-cocaine ([11C]cocaine) studies in normal human volunteers and the results are compared to the standard nonlinear least-squares analysis. The calculated value of Bmax/Kd for the high-affinity binding site for cocaine is 0.62 +/- 0.20, in agreement with literature values.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384545     DOI: 10.1038/jcbfm.1990.127

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  444 in total

1.  Modified regression model for the Logan plot.

Authors:  József Varga; Zsolt Szabo
Journal:  J Cereb Blood Flow Metab       Date:  2002-02       Impact factor: 6.200

2.  In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688.

Authors:  David Elmenhorst; Luciano Minuzzi; Antonio Aliaga; Jared Rowley; Gassan Massarweh; Mirko Diksic; Andreas Bauer; Pedro Rosa-Neto
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

3.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

4.  Characterization of dopamine D1 and D2 receptor function in socially housed cynomolgus monkeys self-administering cocaine.

Authors:  Paul W Czoty; Drake Morgan; Erin E Shannon; H Donald Gage; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2004-02-07       Impact factor: 4.530

Review 5.  Use of positron emission tomography in anticancer drug development.

Authors:  Eric O Aboagye; Patricia M Price
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

6.  Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.

Authors:  Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

7.  Improved kinetic analysis of dynamic PET data with optimized HYPR-LR.

Authors:  John M Floberg; Charles A Mistretta; Jamey P Weichert; Lance T Hall; James E Holden; Bradley T Christian
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

8.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Authors:  Dustin W Wooten; Nicolas J Guehl; Eline E Verwer; Timothy M Shoup; Daniel L Yokell; Nevena Zubcevik; Neil Vasdev; Ross D Zafonte; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

9.  Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves.

Authors:  M Reimold; W Mueller-Schauenburg; G A Becker; G Reischl; B M Dohmen; R Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-19       Impact factor: 9.236

10.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.